Back to Search
DENNIS PRIEBAT, MD
MD
Hematology & Oncology Physician
NPI: 1881648053Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
MD10200(DC)
Research & Publications (8)
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
PMID 19451433·J Clin Oncol·2009
3-trial
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
PMID 19669326·Hepatol Int·2008
8-other
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
PMID 17602081·J Clin Oncol·2007
3-trial
Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group.
PMID 12673725·Cancer·2003
3-trial
Immediate reconstruction after mastectomy for breast cancer does not prolong the time to starting adjuvant chemotherapy.
PMID 11943114·Am J Surg·2002
4-observational
Osteosarcoma: a multidisciplinary approach to diagnosis and treatment.
PMID 11925089·Am Fam Physician·2002
6-review
Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary?
PMID 11456048·Ann Surg Oncol·2001
8-other
Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells.
PMID 11081253·Thyroid·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 110 IRVING ST NW, SUITE 2A38
WASHINGTON, DC 20010 - Phone
- (202) 877-2505
Quick Facts
- NPI
- 1881648053
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 8
Are you this provider?
Claim Your Profile